Kemp Dolliver
Stock Analyst at Brookline Capital
(0.53)
# 3,818
Out of 4,711 analysts
18
Total ratings
33.33%
Success rate
-19.07%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $17 | $8.28 | +105.31% | 1 | Dec 5, 2024 | |
| EYEN Eyenovia | Downgrades: Hold | n/a | $0.09 | - | 2 | Nov 15, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $0.69 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $2.48 | +45.16% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.71 | +1,228.41% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $1.44 | +2,080.56% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $0.32 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $89.29 | +12.00% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $1.73 | +3,194.80% | 2 | Oct 12, 2023 | |
| PROC Procaps Group | Downgrades: Hold | $4.5 | $2.51 | +79.28% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $25 | $2.27 | +1,001.32% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $15.27 | +22.79% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $1.00 | +700.08% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $1.12 | +404.46% | 1 | Feb 2, 2022 |
Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $8.28
Upside: +105.31%
Eyenovia
Nov 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.09
Upside: -
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.69
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $2.48
Upside: +45.16%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.71
Upside: +1,228.41%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.44
Upside: +2,080.56%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.32
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $89.29
Upside: +12.00%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $1.73
Upside: +3,194.80%
Procaps Group
Sep 6, 2023
Downgrades: Hold
Price Target: $4.5
Current: $2.51
Upside: +79.28%
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.27
Upside: +1,001.32%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $15.27
Upside: +22.79%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $1.00
Upside: +700.08%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $1.12
Upside: +404.46%